Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nls Pharmaceutics Ltd (NQ: NLSP )

3.610 +0.180 (+5.24%)
Streaming Delayed Price Updated: 9:51 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nls Pharmaceutics Ltd

< Previous 1 2 3 4 Next >
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
Via ACCESSWIRE
NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split
Via ACCESSWIRE
NLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to Merge
Via ACCESSWIRE
NLS Pharmaceutics Announces Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease Treatments
Via ACCESSWIRE
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements
Via ACCESSWIRE
NLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)
Via ACCESSWIRE
NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol’s Neuroprotective Effects in Narcoleptic-like Rat Model
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing
Via ACCESSWIRE
NLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Announces $1.75 Million Registered Direct Offering
Via ACCESSWIRE
NLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist Platform
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering Event
Via ACCESSWIRE
Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance
Via ACCESSWIRE
NLS Pharmaceutics Submits Plan to Regain Listing Compliance With Nasdaq
Via ACCESSWIRE
Notice of Deficiency with Nasdaq Continued Listing Requirements
Via ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and Commercialize Next Generation Dual Orexin Agonist Platform of Aexon Labs, Inc.
Via ACCESSWIRE
NLS Pharmaceutics Announces Election of Additional Board Members
Via ACCESSWIRE
NLS Pharmaceutics to Participate in the Oppenheimer Sleep Disorders Summit: Deep Dive into Narcolepsy and Idiopathic Hypersomnia
Via ACCESSWIRE
NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Via ACCESSWIRE
NLS Pharmaceuticals to Reschedule Company Update on Strategic Discussions
Via ACCESSWIRE
NLS Pharmaceutics Announces Company Update on Strategic Partnerships
Via ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
NLS Pharmaceutics to Proceed with Phase 3 Clinical Program (AMAZE) for Mazindol ER for the Treatment of Narcolepsy Following FDA Review and IRB Approval of the Full Study Protocol
Via ACCESSWIRE
NLS Pharmaceutics Releases the Results from its Annual General Meeting
Via ACCESSWIRE
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.